Tilray Inc. ($TLRY) Stock Forecast: Up 6.9% Today

What is Tilray Inc.?

Tilray Brands Inc. (TLRY) is a global company that focuses on the production and distribution of beverages, with recent acquisitions in the brewing industry. Today, TLRY experienced a strong bullish movement in the stock market.

Why is Tilray Inc. going up?

TLRY stock is up 6.9% on Mar 10, 2026 15:51

• TLRY's bullish movement can be attributed to its strategic acquisition of BrewDog's Australian assets, including the Brisbane brewery and a network of bars, to expand its presence in the Asia-Pacific region.
• The expansion into Australia serves as a gateway for Tilray to introduce its broader beverage portfolio to new markets, enhancing its global beverage revenues.
• This move not only strengthens Tilray's international brewing footprint but also positions the company to capitalize on the growing demand for craft beverages in the Asia-Pacific market, driving investor optimism and contributing to the bullish market movement of TLRY.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands adds Australian assets to BrewDog buy

Tilray Brands has expanded its acquisition of BrewDog to include the Scottish company's Australian brewing operations and "flagship" bars, following an initial deal for the global rights to the BrewDog brand. This strategic move aims to leverage Australia as a gateway to the Asia Pacific region for Tilray's beverage portfolio. The expansion comes after Tilray's earlier purchase of BrewDog's UK operations and involves further negotiations for US assets, while many of BrewDog's remaining UK bars are set for closure.

https://drinks-intel.com/beer/tilray-brands-adds-australian-assets-to-brewdog-buy/

Tilray buys BrewDog’s Aussie brewery and bars to push into Asia-Pacific

Tilray Brands has acquired BrewDog Brewing Australia, including its Brisbane brewery and a network of bars, establishing Australia as a strategic hub for expansion into the Asia-Pacific beverage market. This acquisition follows Tilray's purchase of BrewDog's UK operations and aims to scale the BrewDog brand nationally in Australia while introducing Tilray's broader beverage portfolio to the region. The deal is expected to significantly contribute to Tilray's global beverage revenues and enhance its international brewing footprint.

https://www.stocktitan.net/news/TLRY/tilray-brands-acquires-brew-dog-australia-establishing-strategic-4z252yz2vx0u.html

Tilray Brands Acquires BrewDog Australia

Tilray Brands Inc. has acquired BrewDog Brewing Australia, including its Brisbane brewing facility and a portfolio of bars. This acquisition is a strategic move to expand Tilray's global beverage and consumer products presence across the Asia-Pacific region, building on its recent acquisition of BrewDog's UK operations. The deal strengthens Tilray's international brewing footprint and provides a hub to introduce its U.S. beverage brands to new markets.

https://www.cannabisbusinesstimes.com/international/news/15819074/tilray-brands-acquires-brewdog-australia

Tilray Brands, Inc. (TLRY) Acquires BrewDog

Tilray Brands, Inc. (NASDAQ:TLRY) has acquired select assets of BrewDog for £33 million, including its global brand and IP, UK brewing operations, and 11 brewpubs. This acquisition is expected to add approximately $200 million in yearly net revenue and $6 million to $8 million in adjusted EBITDA, with cash flow becoming positive in fiscal 2027. Following the transaction, Tilray expects its global beverage platform to generate around $500 million in annual revenue and consolidated annualized revenue of approximately $1.2 billion.

https://www.bitget.com/amp/news/detail/12560605247434

Tilray Brands, Inc. (TLRY) Acquires BrewDog

Tilray Brands, Inc. (NASDAQ: TLRY) has acquired select assets of BrewDog for £33 million, including its global brand, intellectual property, UK brewing operations, and 11 brewpubs. This acquisition is projected to add approximately $200 million in yearly net revenue and $6-8 million in adjusted EBITDA, making the cash flow positive in fiscal 2027. Following this transaction, Tilray expects its overall global beverage platform to generate about $500 million in annual revenue, with consolidated annualized revenue reaching around $1.2 billion.

https://www.insidermonkey.com/blog/tilray-brands-inc-tlry-acquires-brewdog-1711789/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Tilray Inc. Price History

29.00.2026 - TLRY Stock was down 7.2%

• Tilray's stock plummeted by 3.6% recently due to various reasons:
• Analyst downgrades and missing earnings per share (EPS) figures in the most recent report raised concerns among investors, leading to a decline in stock value.
• The stock's movement below its 50-day and 200-day moving averages signifies a pessimistic market sentiment.
• Despite positive updates about expanding its European medical cannabis platform in Italy, the company encounters obstacles like regulatory challenges, competition from multi-state operators, and high short interest, contributing to its overall underwhelming performance.
• Although the announcement of the SweetWater 420 Fest by Tilray's branch, SweetWater Brewing Company, was positive for the brand, it did not notably impact the stock's trajectory.
• Various analysts' price targets and ratings, for instance, Canaccord Genuity Group's hold rating and a price target of C$13.00, depict a cautious outlook on Tilray's stock performance in the near future.
• Investors keenly observe developments regarding the potential reclassification of U.S. medical cannabis and the company's efficacy in managing losses to evaluate future stock performance amidst previous declines and dilution risks.

10.02.2026 - TLRY Stock was up 6.9%

• TLRY's bullish movement can be attributed to its strategic acquisition of BrewDog's Australian assets, including the Brisbane brewery and a network of bars, to expand its presence in the Asia-Pacific region.
• The expansion into Australia serves as a gateway for Tilray to introduce its broader beverage portfolio to new markets, enhancing its global beverage revenues.
• This move not only strengthens Tilray's international brewing footprint but also positions the company to capitalize on the growing demand for craft beverages in the Asia-Pacific market, driving investor optimism and contributing to the bullish market movement of TLRY.

24.01.2026 - TLRY Stock was up 5.3%

• Despite a new exclusive licensing deal for beer distribution in the U.S. with Carlsberg, Tilray's stock continues to struggle, reflecting ongoing financial difficulties and consistent share price decline.
• The company's active acquisition strategy and continual cash consumption have led to a decrease in shareholder value, prompting analysts to recommend exploring other investment options.
• Despite a slight decrease in Tilray's stock value during a bullish market period, investors are eagerly awaiting the upcoming earnings report, hoping for positive growth in both earnings per share and revenue for the quarter.
• The exclusive U.S. licensing agreement with Carlsberg aims to enhance Tilray's presence in the beverage market but market sentiment remains cautious due to the company's historical performance and limited growth prospects.

22.00.2026 - TLRY Stock was up 5.1%

• TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
• The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
• Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
• The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

19.01.2026 - TLRY Stock was up 5.8%

• Tilray's stock experienced a strong bullish movement of over 4% following the announcement of the exclusive brewing and licensing agreement with Carlsberg Group.
• The partnership with Carlsberg is expected to bring immediate scale and revenue to Tilray, driving optimism among investors and leading to the bullish market movement.
• This strategic move aligns with Tilray's focus on partnering with established brands and maximizing its beverage operations, showcasing a promising future for the company in the competitive beer market.
• The market's positive reaction reflects investor confidence in Tilray's ability to leverage its operational infrastructure effectively and strengthen its position in the premium European segment of the US beer market.

05.01.2026 - TLRY Stock was down 6.6%

• The acknowledgment of Tilray Pharma's CC Pharma as a TOP 100 Innovator in Germany underlines the company's dedication to innovation and operational excellence within the pharmaceutical distribution industry.
• Notwithstanding this positive development, the decrease in Tilray Brands shares could be linked to profit-taking by investors following a recent uptrend or broader market uncertainties impacting the stock price.
• The forthcoming nationwide promotional campaign in Tilray's U.S. craft beer taprooms might have shifted investor attention away from the pharmaceutical sector, resulting in a temporary decline in the stock price.
• Investors may be anticipating the upcoming financial update in early April to evaluate the company's overall performance and growth trajectory, possibly influencing the bearish sentiment surrounding the stock today.

28.00.2026 - TLRY Stock was down 5.2%

• Analyst downgrades and a significant earnings per share (EPS) miss contributed to a 3.6% drop in Tilray Brands' shares, leading to the stock trading below its key moving averages.
• Despite some institutional investment interest, the company reported a deeply negative net margin and is projected to have a negative EPS for the current year, impacting investor sentiment.
• The expansion of Tilray's European medical cannabis platform through Italy was seen as a positive move, but investors are still awaiting progress on U.S. medical cannabis reclassification and effective management of losses to mitigate risks.
• The launch of a new high-ABV beer by SweetWater Brewing Company, a subsidiary of Tilray Brands, did not seem to have a significant impact on the stock's bearish movement today.

16.00.2026 - TLRY Stock was down 5.1%

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

15.00.2026 - TLRY Stock was up 5.3%

• Tilray reported record Q2 revenues of $218 million, driven by international operations and distribution, showcasing the company's ability to capture market opportunities.
• Despite a recent EPS miss and negative net margins, the stock saw an increase as investors may be optimistic about the company's long-term growth prospects.
• The focus on higher-margin international markets and new THC beverage offerings indicates Tilray's commitment to diversification and sustainable profitability, which could have positively influenced investor sentiment.
• Analysts suggesting to consider other stocks for better investment opportunities may have created some uncertainty, but the overall market movement reflects confidence in Tilray's strategic direction and potential for future growth.

05.02.2026 - TLRY Stock was down 5.2%

• The purchase of BrewDog brand and assets may have sparked initial investor interest, but the subsequent stock decline suggests concerns over deal execution or financial impacts.
• Despite expansions in product lines and partnerships, overall market sentiment and uncertainties about the upcoming earnings report likely contributed to TLRY's bearish movement.
• Good Supply's introduction of high-THC products could have provided a small boost, but the limited availability and regional exclusivity may not have been enough to counter broader market pressures.
• TLRY's stock outperformance in the last month despite sector challenges highlights investor scrutiny, particularly with the upcoming earnings report shaping market sentiments.

18.01.2026 - TLRY Stock was up 5.5%

• An analyst has given TLRY a Hold rating and set a price target of C$13, expressing concerns about the beer market and optimism regarding potential US legislation impact.
• Despite falling short of Q4 earnings projections and recording a negative net margin, Zacks Research upgraded its rating on TLRY from "strong sell" to "hold."
• A recent partnership with Smartway Pharmaceuticals to enhance the distribution of medical cannabis products in the UK has been seen as a strategic move that likely boosted investor confidence and contributed to positive stock movement.
• Institutional investors making changes to their holdings by either increasing or starting new positions in TLRY may have helped drive the stock price upwards.

10.01.2026 - TLRY Stock was up 5.2%

• Tilray's stock showed a robust 1.6% bullish movement today, disregarding recent downgrades and cautious analyst views.
• Q2 FY2026 saw the company achieving record net revenue due to growth in international medical cannabis sales and Canadian adult-use cannabis. This demonstrates its ability to navigate market fluctuations.
• The company's expansion of its U.S. beverage alcohol division and recognition of its German medical distribution subsidiary showcase strategic efforts to diversify revenue sources and bolster presence in key markets.
• Notwithstanding challenges like missed earnings estimates and negative net margin, Tilray's dual focus on medical cannabis and spirits sectors, along with international expansion, appears to have positively impacted investor sentiment and influenced today's bullish movement.